| __timestamp | Amphastar Pharmaceuticals, Inc. | Apellis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 2908166 |
| Thursday, January 1, 2015 | 46974000 | 6356782 |
| Friday, January 1, 2016 | 47298000 | 4303743 |
| Sunday, January 1, 2017 | 50918000 | 10463151 |
| Monday, January 1, 2018 | 58044000 | 22639184 |
| Tuesday, January 1, 2019 | 63109000 | 67046483 |
| Wednesday, January 1, 2020 | 65157000 | 139401000 |
| Friday, January 1, 2021 | 68920000 | 176771000 |
| Saturday, January 1, 2022 | 66592000 | 277163000 |
| Sunday, January 1, 2023 | 80393000 | 500815000 |
Cracking the code
In the competitive world of pharmaceuticals, managing expenses is crucial for sustained growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Apellis Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. over the past decade.
From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, starting at $40 million and reaching $80 million. Meanwhile, Apellis experienced a staggering increase of over 17,000%, from a modest $2.9 million to a substantial $500 million. This dramatic rise highlights Apellis's aggressive expansion strategy.
While Amphastar's expenses grew steadily, Apellis's rapid increase suggests a focus on scaling operations and market penetration. Investors and industry analysts should consider these trends when evaluating the companies' financial health and strategic direction.
Understanding these expense trends provides valuable insights into the operational strategies of these pharmaceutical leaders.
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Novartis AG vs Apellis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Amphastar Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Rhythm Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Perrigo Company plc or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.